NEWTON, Mass.--(BUSINESS WIRE)--Allena Pharmaceuticals, Inc., a company developing and commercializing innovative non-systemic oral protein therapeutics to treat metabolic and orphan diseases, with a particular focus on nephrologic and urologic conditions, today announced the appointment of Gino Santini to the company’s board of directors. Mr. Santini most recently served as senior vice president of corporate strategy and business development at Eli Lilly and Company, where he led corporate strategy and long-range planning, M&A, new product licensing, innovative financing of internal development projects and the expansion of Lilly Ventures in the U.S. and China.
